Vol. 6 No. 11 (2026): November
Reimbursement Reviews

Retifanlimab (Zynyz)

decorative image of the issue cover

Published November 19, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Retifanlimab (Zynyz), 500 mg/20 mL (25 mg/mL), concentrate for solution, IV infusion.
  • Indication: In combination with carboplatin and paclitaxel for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent SCAC.